Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.51 +5.14%

+$0.45 today

Market cap
$53.05M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.00M

Average 0.05M

Big Five Numbers

Xilio Therapeutics, Inc. growth analysis

Start with the long-run numbers that show whether XLO compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
Not availableNot availableNot availableNot available
Revenue
Not availableNot availableNot available+589.9%
Equity
Not availableNot available-80.2%-90.8%
Cash
Not availableNot available+4.5%+148.7%
ROIC
Not available-89.5%-113.5%-42.1%

Analysis

In the latest year, Revenue was strongest at +589.9%, while Equity was weakest at -90.8%. The three-year average ROIC was -113.5%, a measure of how efficiently the company earned that growth.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
-35.1% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Forward estimates point to Revenue at -35.1% (5yr), giving you a quick read on expected growth from here.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where XLO earns its revenue, as reported in company filings

This company does not report revenue segments.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$35.0M
+ D&A$1.5M
+ Stock-Based Comp$6.9M
+ Deferred Tax$0
+ Working Capital$25.1M
- Other Non-Cash-$3.6M
= Operating Cash Flow-$5.0M
- Capex-$518.0K
= Free Cash Flow-$5.5M

Analysis

FY2025 free cash flow is -$5.5M. FCF conversion is 15.7% of net income. Operating cash flow was -$5.0M, with capex of -$518.0K. The largest bridge item is Working Capital at $25.1M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for XLO.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for XLO.

Sign in free

Competitor growth

How does Xilio Therapeutics, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

OnKure Therapeutics, Inc.

OKUR

$106.52M———
—0 analysts

Actinium Pharmaceuticals, Inc.

ATNM

$51.56M——-55.6%
+140.9% (5yr)2 analysts

PDS Biotechnology Corporation

PDSB

$48.70M———
—1 analysts

Questions

Growth questions

Common questions about XLO's growth, answered from reported and forecast figures.

Is XLO growing revenue?

Revenue grew 589.9% year over year, from $6.34M to $43.77M.

Is XLO turning growth into profit?

The latest net margin is -80.1%, which shows how much revenue became net income.